Abstract:Abstract Background Empagliflozin (EMPA) is a widely used medication in the treatment of Type 2 diabetes Mellitus (T2DM). It functions by inhibiting glucose reabsorption by the kidneys, which helps lower blood glucose levels. Studies have shown that there is a bidirectional relationship between oral medications and the gut microbiota. The gut microbiota is one of the most complex and diverse microbial communities in the body, with dysbiosis being closely associated with various metabolic diseases, such as diabetes, obesity, and cardiovascular diseases. Therefore, the aim of this study was to investigate the effects of EMPA on the gut microbiota of T2DM mice, in order to further elucidate its potential roles in blood glucose control and cardiovascular protection. Methods and Results We intervened with db/db mice for 20 weeks, measuring blood glucose during the intervention and blood lipids after the intervention. We collected fecal samples from the mice before and after the intervention, ensuring that the samples were uncontaminated by collecting them from the anus. Through bioinformatics analysis using 16S rRNA sequencing, we identified changes in key genus of gut microbiota in these mice. In addition to the conventional abilities of reducing blood glucose and blood lipids, we found that the impact of EMPA on gut microbiota could not be ignored. EMPA significantly changed the diversity and richness index of gut microbiota in db/db mice, such as the sobs and simpsons index. EMPA changed the β-diversity of gut microbiota, altering the complexity between different bacterial genus to be similar to that of healthy mice. EMPA also increased the abundance of species such as Clostridium_innocuum_group, Rikenellaceae, Alistipes, Prevotellaceae_UCG-001, Eubacterium_siraeum_group, Anaeroplasma, and Odoribacter, while decreasing the abundance of species such as Eubacterium_ventriosum_group, Fusobacterium, Hydrogenoanaerobacterium, Tyzzerella, Prevotellaceae_NK3B31_group, Aerococcaceae, and Aerococcus. Spearman correlation networks analysis showed that Alistipes, Odoribacter, and Anaeroplasma were significantly negatively correlated with blood glucose levels, while Aerococcus was significantly positively correlated with Total cholesterol (TC) and Total triglycerides (TG). EMPA also reduced the functional abundance of gut microbiota related to "Membrane transport," "Xenobiotics biodegradation and metabolism," and "Immune disease." EMPA may achieve its partial blood glucose-lowering and cardiovascular disease-improving effects by impacting these key species and functional abundance of gut microbiota. Conclusion In conclusion, our 20-week intervention on db/db mice showed that EMPA not only had a significant impact on blood glucose and lipids but also on the diversity and richness of gut microbiota. EMPA altered the abundance and ratio of Firmicutes and Bacteroidota, increased beneficial species, and decreased harmful ones. Spearman network analysis revealed the correlation between specific gut microbes and blood glucose and lipid levels. EMPA also decreased the functional abundance of "Membrane transport," "Xenobiotics biodegradation and metabolism," and "Immune disease" pathways. Our findings suggest that EMPA's therapeutic effects may partly arise from its modulation of gut microbiota.

Empagliflozin Modify Gut Microbiota in Db/db Mice Correlating with the Improvement of Glucose and Lipid Metabolism

Empagliflozin Ameliorates Type 2 Diabetes Mellitus-Related Diabetic Nephropathy Via Altering the Gut Microbiota

Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice

SGLT2 inhibitor-empagliflozin treatment ameliorates diabetic retinopathy manifestations and exerts protective effects associated with augmenting branched chain amino acids catabolism and transportation in db/db mice

Cardiovascular Benefits of Empagliflozin Are Associated with Gut Microbiota and Plasma Metabolites Intype 2 Diabetes

Cardiovascular Benefits of Empagliflozin Are Associated With Gut Microbiota and Plasma Metabolites in Type 2 Diabetes

Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study

Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function

Eicosapentaenoic and Docosahexaenoic Acids Attenuate Hyperglycemia Through the Microbiome-Gut-organs Axis in Db/db Mice.

Integrated Multi-Omics Analyses Reveal Effects of Empagliflozin on Intestinal Homeostasis in High-Fat-diet Mice

Empagliflozin Inhibits Coronary Microvascular Dysfunction and Reduces Cardiac Pericyte Loss in Db/db Mice

Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora

Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes

Investigating the impact of empagliflozin on the retina of diabetic mice

Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes

Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy

Empagliflozin alleviates podocytopathy and enhances glomerular nephrin expression in db/db diabetic mice

Multi-omics analysis reveals attenuation of cellular stress by empagliflozin in high glucose-treated human cardiomyocytes

Metabolic and Hepatic Effects of Empagliflozin on Nonalcoholic Fatty Liver Mice

Nascent shifts in renal cellular metabolism, structure, and function due to chronic empagliflozin in prediabetic mice

Empagliflozin attenuates liver fibrosis in high‐fat diet/streptozotocin‐induced mice by modulating gut microbiota